- TapImmune (TPIV) announces that the first patient has been enrolled in a Phase 2 clinical trial of TapImmune's therapeutic vaccine candidate TPIV200.
- The 280-patient trial, received $13.3M in grant funding from the U.S. Department of Defense to evaluate the prevention of cancer recurrence in women with triple-negative breast cancer who have completed first-line surgery and radiotherapy/chemotherapy.
- TPIV200 is a peptide-based cancer vaccine that has been shown to induce a robust and long-lasting "memory" T-cell immune response directed against folate receptor alpha.